All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-09-21T06:55:19.000Z

Gilteritinib in FLT3 AML

By Claire Baker
Featured
Naval Daver
Sep 21, 2020
Share:

Bookmark this article

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub was pleased to speak to Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US, about gilteritinib for the treatment of FLT3 AML.

Gilteritinib in FLT3 AML

Gilteritinib is a FLT3 inhibitor which is FDA approved for the treatment of R/R FLT3-mutated AML. This approval was based on the phase III ADMIRAL trial, which evaluated gilteritinib vs investigator-choice chemotherapy. Data from the ADMIRAL study show that gilteritinib demonstrated a positive outcome for both of the study primary endpoints (overall survival and complete remission/complete remission with partial hematologic recovery).

Naval Daver concludes by outlining the next steps for gilteritinib in the AML setting.

More about...
ADMIRALGilteritinibSOHO 2020

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 1 day left ...

Related articles

Add bookmark

How can venetoclax combinations improve outcome for FLT3-mutant AML?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax...

Feb 25, 2022
Add bookmark

How can venetoclax combinations improve outcome for FLT3-mutant AML?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center,...

Feb 25, 2022
Add bookmark

August 2019 | Druggable mutations in AML

This month's educational theme in acute myeloid leukemia surrounds druggable muations. Here, we summarise our past content on this theme.

Aug 7, 2019
Add bookmark

August 2019 | Druggable mutations in AML

This month's educational theme in acute myeloid leukemia surrounds druggable muations. Here, we summarise our past content on this theme.

Aug 7, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox